These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33713579)

  • 21. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Organoid Swelling and
    Graeber SY; van Mourik P; Vonk AM; Kruisselbrink E; Hirtz S; van der Ent CK; Mall MA; Beekman JM
    Am J Respir Crit Care Med; 2020 Dec; 202(11):1589-1592. PubMed ID: 32687398
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of Ivacaftor in Three Pediatric Siblings With Cystic Fibrosis Carrying the Mutations G551D And F508del.
    Mainz JG; Arnold C; Hentschel J; Tabori H
    Arch Bronconeumol (Engl Ed); 2018 Apr; 54(4):232-234. PubMed ID: 29103672
    [No Abstract]   [Full Text] [Related]  

  • 24. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
    Schneider EK; Reyes-Ortega F; Li J; Velkov T
    Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.
    Colombo C; Foppiani A; Bisogno A; Gambazza S; Daccò V; Nazzari E; Leone A; Giana A; Mari A; Battezzati A
    J Endocrinol Invest; 2021 Oct; 44(10):2213-2218. PubMed ID: 33586024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
    Lommatzsch ST; Taylor-Cousar JL
    Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
    Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
    Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
    Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
    Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pregnancy among cystic fibrosis women in the era of CFTR modulators.
    Heltshe SL; Godfrey EM; Josephy T; Aitken ML; Taylor-Cousar JL
    J Cyst Fibros; 2017 Nov; 16(6):687-694. PubMed ID: 28190780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 32. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
    Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
    J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
    Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
    N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis.
    Kopp BT; McCulloch S; Shrestha CL; Zhang S; Sarzynski L; Woodley FW; Hayes D
    Pediatr Pulmonol; 2018 May; 53(5):583-591. PubMed ID: 29461009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
    Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C
    Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.